Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Big Reversal: Actavis Now Plans China Expansion, Post-Allergan

publication date: Nov 25, 2014
In January of this year, Paul Bisaro, Chairman and CEO of Actavis, declared the company would exit China: the regulatory system was too unpredictable and the profit margins too small, he said. In the ten months since then, Actavis has become a different company because of two giant acquisitions: first Forest Labs and more recently Allergan, a $66 billion transaction. It also has a new CEO: Brent Saunders, who had been CEO of Forest Labs. Actavis officials told Bloomberg that the Allergan takeover would involve job losses for some people, but China would now become a growth area. More details....

Stock Symbol: (NYSE: ACT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital